Sanjivani Paranteral Ltd. specializes in Pharmaceuticals within the Healthcare sector.
Sanjivani Paranteral Ltd., with Security Code 531569, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | 128.64 | 12.58 | 129.17 | 1.08 | - | 0.53 | -2.38 | 18.84 |
2023-10-01 | 2023-12-31 | 149.63 | 16.51 | 152.17 | 1.65 | - | 2.54 | -2.35 | 19.01 |
2023-07-01 | 2023-09-30 | 140.03 | 17.06 | 141.53 | 1.71 | - | 1.50 | -2.32 | 19.86 |
2023-04-01 | 2023-06-30 | 125.81 | 15.50 | 126.41 | 1.55 | - | 0.60 | -2.29 | 18.00 |
Compounded Sales Growth | |
---|---|
10 Years: | -10% |
5 Years: | 17% |
3 Years: | 29% |
TTM: | 31% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 38% |
3 Years: | 63% |
TTM: | 37% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 94% |
3 Years: | 122% |
1 Year: | 219% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
1 Year: | 0% |
Sanjivani Parenterals Limited (SPL), a leading manufacturer of injectable pharmaceuticals in India, today announced its financial results for the third quarter ended December 31, 2022.
Sanjivani Parenterals Limited (SPL), a leading manufacturer of injectable pharmaceuticals in India, has reported a consolidated revenue of Rs. 218.2 crore for the third quarter ended December 31, 2022, marking a rise of 17% compared to the corresponding quarter of the previous fiscal year (Q3 FY22).
Sanjivani Parenterals Limited (SPL), a leading manufacturer of injectable pharmaceuticals in India, has made significant strides in expanding its market presence in Central and Eastern Europe. The company recently received marketing authorizations for its key products in several countries within these regions, including Poland, Hungary, Romania, and Bulgaria.